发明名称 CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT
摘要 Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I(011) with respect to a sum total of I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) respectively in relation to the diffraction peaks detected in a range of 2θ=5 to 35° in a powder X-ray diffractometry using CuKα radiation.;
申请公布号 US2015368233(A1) 申请公布日期 2015.12.24
申请号 US201314388218 申请日期 2013.06.24
申请人 POLA PHARMA INC. ;NIHON NOHYAKU CO., LTD. 发明人 MASUDA Takaaki;MIYATA Yoshiyuki;KANEDA Hideo
分类号 C07D409/06 主分类号 C07D409/06
代理机构 代理人
主权项 1. A crystal of luliconazole represented by the following formula, wherein the crystal is recrystallized from alcohol which may contain water, and the crystal has such a crystal habit that (011) plane is a specific crystal growth plane, and the crystal is characterized by crystal system of monoclinic crystal, space group of P21, lattice constant of a=9.0171(9) Å, b=8.167(1) Å, c=10.878(1) Å, β=95.917(9) °, R factor of R=0.046, Rw=0.047:
地址 Tokyo JP